Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rudy

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Journal of Medical Ethics|January 26, 2013
Comprehension of a simplified assent form in a vaccine trial for adolescentsSonia Lee, Bill G Kapogiannis, Patricia M Flynn, et al.
Sexually Transmitted Diseases|October 29, 2021
Rates of Sexually Transmitted Infection Diagnoses Among US Youth With Perinatally and Nonperinatally Acquired HIVAnne M Neilan, Justin B DeMonte, Julia H A Foote, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 6, 2015
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061Bret J Rudy, Bill G Kapogiannis, Carol Worrell, et al.
Nature Communications|February 10, 2026
Rational design and in vivo validation of capsid inhibitors for enterovirus D68Kan Li, Michael J Rudy, Thomas Klose, et al.
Lancet (London, England)|January 25, 2016
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialBarry Greenberg, Javed Butler, G Michael Felker, et al.
Nature Communications|July 2, 2025
A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysisKan Li, Michael J Rudy, Yanmei Hu, et al.
The Journal of Infectious Diseases|June 25, 2004
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapyPatricia M Flynn, Bret J Rudy, Steven D Douglas, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Long-term observation of adolescents initiating HAART therapy: three-year follow-upPatricia M Flynn, Bret J Rudy, Jane C Lindsey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
HIV Continuum of Care for Youth in the United StatesMichelle A Lally, Jacob J van den Berg, Andrew O Westfall, et al.
Journal of Neurovirology|October 15, 2015
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIVSharon L Nichols, James Bethel, Bill G Kapogiannis, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Medical Ethics|January 26, 2013
Comprehension of a simplified assent form in a vaccine trial for adolescentsSonia Lee, Bill G Kapogiannis, Patricia M Flynn, et al.
Sexually Transmitted Diseases|October 29, 2021
Rates of Sexually Transmitted Infection Diagnoses Among US Youth With Perinatally and Nonperinatally Acquired HIVAnne M Neilan, Justin B DeMonte, Julia H A Foote, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 6, 2015
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061Bret J Rudy, Bill G Kapogiannis, Carol Worrell, et al.
Nature Communications|February 10, 2026
Rational design and in vivo validation of capsid inhibitors for enterovirus D68Kan Li, Michael J Rudy, Thomas Klose, et al.
Lancet (London, England)|January 25, 2016
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialBarry Greenberg, Javed Butler, G Michael Felker, et al.
Nature Communications|July 2, 2025
A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysisKan Li, Michael J Rudy, Yanmei Hu, et al.
The Journal of Infectious Diseases|June 25, 2004
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapyPatricia M Flynn, Bret J Rudy, Steven D Douglas, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Long-term observation of adolescents initiating HAART therapy: three-year follow-upPatricia M Flynn, Bret J Rudy, Jane C Lindsey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 10, 2017
HIV Continuum of Care for Youth in the United StatesMichelle A Lally, Jacob J van den Berg, Andrew O Westfall, et al.
Journal of Neurovirology|October 15, 2015
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIVSharon L Nichols, James Bethel, Bill G Kapogiannis, et al.
Pageof 11